Choroidal neovascularisation in pathological myopia: an update in management

Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization

“…Seventeen (Figure 3). For the ranibizumab group, the mean number of injections was also 3.8 (range, [3][4][5][6]. Eleven (73.3%) eyes required only three initial intravitreal ranibizumab injections.…”

“…3,4 Photodynamic therapy (PDT) with verteporfin has been used for treating myopic CNV in the past decade and studies have shown that PDT might reduce the risk of visual loss compared with placebo. 5,6 However, the long-term outcome of PDT is not favourable as patients generally had no improvement in mean visual acuity following treatment and the beneficial effect of PDT in preventing visual loss was no longer significant at 2 years. 6,7 In the past few years, various studies have demonstrated the short-term efficacy of intravitreal antivascular endothelial growth factor (VEGF) agents in treating myopic CNV, including both bevacizumab [8][9][10][11][12][13][14][15][16][17][18] and ranibizumab.…”

“…5,6 However, the long-term outcome of PDT is not favourable as patients generally had no improvement in mean visual acuity following treatment and the beneficial effect of PDT in preventing visual loss was no longer significant at 2 years. 6,7 In the past few years, various studies have demonstrated the short-term efficacy of intravitreal antivascular endothelial growth factor (VEGF) agents in treating myopic CNV, including both bevacizumab [8][9][10][11][12][13][14][15][16][17][18] and ranibizumab. [18][19][20][21][22][23][24][25] Most of the studies have demonstrated significant mean visual improvement after anti-VEGF therapy and the beneficial effects were maintained at 12 months.…”

Visual function 5 years or more after macular translocation surgery for myopic choroidal neovascularisation and age-related macular degeneration

“…When the change of the BCVA was ±42 logMAR units, the change was taken to be significant. The VFs were determined by Goldmann perimetry (with V-4), and the area of the VF in degrees 2 was measured with the SCION Image software (NIH, Bethesda, MD, USA). When the VF area changed by ± 430%, it was taken to be a significant decrease.…”

“…High myopia can also lead to visual reductions and development of a CNV (myopic CNV (mCNV)). 2 At present, an intravitreal injection of antivascular endothelial growth factor is generally used to treat CNVs. However, if the retinal pigment epithelium (RPE) underlying the fovea is damaged, the effectiveness of this therapy on the visual acuity (VA) is limited.…”